GenASIs requires automated UroVysion scanning and analysis to a new level.

ASI’s manual and automated scanning system and image evaluation systems enable laboratories to supply highly dependable UroVysion test outcomes quickly and cost-efficiently. Dr.’ Dr. Dominguez further added that ‘The combined microscope and computer-aided picture analysis capabilities of GenASIs help us give quicker and more accurate scientific results. GenASIs takes automated UroVysion scanning and evaluation to a fresh level.’ Limor Shiposh, ASI’s Chief Executive Officer said, ‘We are very happy to have received this essential FDA clearance.Carl H. June at the Abramson Cancers Center of the University of Pennsylvania and Dr. Aaron Rapoport of the University of Maryland Greenebaum Cancer Center developed the analysis design, which was shown to the National Institutes of Health Recombinant DNA Advisory Committee this past year. Dr. June is the regulatory sponsor for the analysis, and Dr. Edward Stadtmauer may be the lead scientific investigator at the Abramson Tumor Center. Dr. Rapoport may be the lead clinical investigator at the University of Maryland. Adaptimmune Ltd is the financial sponsor and owns the core T cell receptor technology. Multiple myeloma is certainly a hematologic cancer localized to the bone marrow.S. Rapoport, Stadtmauer and June have collaborated and extensively released on three prior clinical trials evaluating T cell infusion post ASCT, and have demonstrated that the procedure is safe and promotes reconstitution of the disease fighting capability.